Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2024

Jun 5, 2024

31801_dirs_2024-06-05_c8ee7eed-17a3-48e4-b8f2-554c1e4c6a35.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-06-03

Reporting Person: Jimenez Freddy A. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-06-03 Common Stock M 8006 $10.38 Acquired 33930 Direct
2024-06-03 Common Stock S 8006 $33.6001 Disposed 25924 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-06-03 Incentive Stock Option (Right to Buy) $10.38 M 8006 Disposed 2030-06-18 Common Stock (8006) Direct

Footnotes

F1: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.